Japan Study: Could Continuous Glucose Monitors Benefit Type 2 Diabetes Patients?

A study from Japan is laying the groundwork for one of the most comprehensive reviews ever conducted on continuous glucose monitoring (CGM) technology for people living with Type 2 diabetes. Researchers at Kyoto University's Department of Health Informatics are leading this Cochrane Review protocol — a gold-standard type of medical research that systematically analyzes all available evidence on a treatment or technology.

What Is This Research About?

Most Americans associate CGM devices — small sensors worn on the arm or abdomen that track blood sugar around the clock — with Type 1 diabetes management. But this Japanese research initiative is asking a critically important question: Can CGM technology meaningfully help the tens of millions of Americans living with Type 2 diabetes?

The Kyoto University team is evaluating three specific types of CGM systems:

• Real-time CGM — continuously displays live glucose readings (measured in mg/dL in the US)
• Intermittently scanned CGM — like the popular FreeStyle Libre, requires a manual scan to display readings
• Professional CGM — worn temporarily and reviewed by a clinician

The review will compare these devices against the current standard of care, which includes HbA1c blood tests (the familiar A1C test measuring average blood sugar over 2–3 months), fructosamine tests, and traditional self-monitoring of blood glucose (SMBG) using finger-stick readings. In the US, the American Diabetes Association (ADA) recommends an A1C target below 7% for most non-pregnant adults with diabetes — equivalent to an average blood glucose of approximately 154 mg/dL.

Why the International Perspective Matters

Japan provides a uniquely valuable research lens for American patients. Japan's aging population, universal healthcare system, and high rates of Type 2 diabetes create research conditions that reveal patterns — particularly around elderly patients and underserved communities — that US studies sometimes overlook. Importantly, the Kyoto team is specifically examining health equity, studying how CGM effectiveness varies across different generations, geographic regions, and educational backgrounds. This mirrors growing concerns in the US about diabetes technology access gaps among lower-income and rural patients.

Benefits and Risks Being Examined

The researchers will investigate whether CGM helps Type 2 patients achieve better blood glucose control and prevents serious complications including nerve damage, kidney disease, and vision loss. On the risk side, they will examine skin-related problems such as rashes, adhesive reactions, and sensor-site irritation — real concerns for long-term wearers.

Why This Matters for US Patients

Currently, CGM use for Type 2 diabetes patients in the US is growing but inconsistent. Medicare and many private insurers have expanded CGM coverage for non-insulin-dependent Type 2 patients in recent years, yet many patients and even physicians remain uncertain about its value for this population. This Cochrane Review from Japan could provide the definitive evidence needed to update US clinical guidelines, expand insurance coverage, and help millions of Americans with Type 2 diabetes access technology that may dramatically improve their daily glucose management and long-term health outcomes.

When completed, this review could reshape how American endocrinologists and primary care physicians recommend CGM devices to the estimated 38 million Americans living with diabetes.

Source: Kataoka, Tsuge, Kataoka. "Continuous glucose monitoring systems for adolescents and adults living with type 2 diabetes mellitus." The Cochrane Database of Systematic Reviews, 2025. PMID: 41041869. DOI: 10.1002/14651858.CD016111